ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s What Happened

Shares of ImmuCell Corporation (NASDAQ:ICCC) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.14 and traded as high as $6.16. ImmuCell shares last traded at $6.08, with a volume of 11,053 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “hold (c-)” rating on shares of ImmuCell in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.

ImmuCell Stock Up 0.3%

The firm has a market capitalization of $55.00 million, a PE ratio of 32.00 and a beta of 0.30. The business’s 50 day simple moving average is $6.22 and its 200 day simple moving average is $6.14. The company has a current ratio of 3.85, a quick ratio of 1.99 and a debt-to-equity ratio of 0.28.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, August 14th. The biotechnology company reported $0.06 EPS for the quarter. ImmuCell had a net margin of 6.23% and a return on equity of 6.25%. The business had revenue of $6.45 million during the quarter.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC grew its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 as of its most recent filing with the Securities & Exchange Commission. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.